查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601188

药品製造市场：依配方、药物开发类型、给药途径、药物、年龄层、通路、治疗领域 - 2025-2030 年全球预测

Pharmaceutical Manufacturing Market by Formulation (Capsules, Injectable, Powders), Drug Development Type (In-House, Outsource), Route of Administration, Drugs, Age Group, Distribution Channel, Therapy Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年药品製造市场价值为6,206.8亿美元，预计2024年将达到6,724.4亿美元，复合年增长率为8.66%，到2030年将达到11.1017亿美元。

药品製造部门涵盖药品和医疗疗法的生产、开发和商业化，重点在于药品生产的品质、效率和安全性。全球健康需求不断增长、慢性病盛行率不断上升以及对创新治疗的持续需求推动了对该领域的需求。其应用范围包括 A​​PI（活性药物成分）的生产、最终剂型的配製以及生物技术的进步。最终用途包括医院、诊所、研究机构、零售药局等。影响该市场的关键成长要素包括自动化和人工智慧整合等技术进步、研发投资的增加以及政府的支援措施。此外，个人化医疗和生技药品的成长趋势带来了巨大的成长机会。公司可以透过投资生技研发、提高产能以及采用永续实践来减少对环境的影响，从而利用这些趋势。

主要市场统计
基准年[2023] 6206.8亿美元
预测年份 [2024] 6724.4亿美元
预测年份 [2030] 11,101.70亿美元
复合年增长率（%） 8.66%

然而，市场面临一些限制和挑战，包括严格的监管要求、高昂的药物开发成本以及与生物技术整合相关的复杂性。全球大流行也凸显了供应链的脆弱性，并强化了对更具弹性系统的需求。鼓励市场相关人员探索创新领域，例如数位健康工具、先进的药物输送系统以及利用巨量资料分析来优化製造流程。此外，由于医疗保健支出的增加，新兴国家提供了市场扩张机会。市场竞争激烈，创新压力持续存在，需要灵活的策略来维持市场占有率。公司应注重合作伙伴关係、开放式创新和策略性收购，以推动成长并克服现有障碍。整体而言，市场格局的特点是由科学创新和监管环境驱动的动态性，相关人员必须保持积极主动的策略方法，才能在这个充满挑战的环境中取得成功。

市场动态：揭示快速发展的药品製造市场的关键市场洞察

供需的动态交互作用正在改变药品製造市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球对疫苗和药物的需求增加
    • 医药品研究开发费用增加
    • 老年人口增加和慢性病发生率增加
  • 市场限制因素
    • 与药品製造相关的高成本和复杂性
  • 市场机会
    • 增加药品製造领域的投资和融资计划
    • 新药品製造技术的出现
  • 市场问题
    • 政府对製药公司的严格监管

波特五力：驾驭药品製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解药品製造市场的外部影响

外部宏观环境因素在塑造药品製造市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解药品製造市场的竞争格局

对药品製造市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：药品製造市场供应商绩效评估

FPNV定位矩阵是评估药品製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球对疫苗和药物的需求增加
      • 医药品研究开发费用增加
      • 老年人口增加和慢性病发生率增加
    • 抑制因素
      • 与药品製造相关的高成本和复杂性
    • 机会
      • 加大医药製造领域投资金筹措力度
      • 新药品製造技术的出现
    • 任务
      • 政府对製药公司的严格监管
  • 市场区隔分析
    • 配方：投资激增以支持注射剂的强劲研发
    • 药物开发类型：由于成本效益，外包药物生产的使用增加
    • 给药途径：随着慢性病盛行率的不断增加，肠外给药的研发活动不断增加。
    • 药品：非处方药 (OTC) 的趋势
    • 年龄层：非常需要药物组合来治疗老年人的疾病
    • 分销通路：药品非零售通路的渗透
    • 治疗领域：开发新肿瘤治疗方法的创新浪潮
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化
    • 2022 年最畅销组合药物和非处方药列表

第六章 药品製造市场：依配方分类

  • 介绍
  • 胶囊
  • 注射
  • 粉末
  • 喷
  • 暂停
  • 锭剂

第七章药品製造市场：依药物开发类型

  • 介绍
  • 公司内部
  • 外包

第八章 药品製造市场：依管理途径分类

  • 介绍
  • 吸入
  • 口服
  • 胃肠外的
  • 局部的

第九章药品製造市场：依药品分类

  • 介绍
  • 非处方药 (OTC)
  • 联合用药

第10章药品製造市场：依年龄组别

  • 介绍
  • 成人
  • 婴儿和青少年
  • 老年人

第十一章药品製造市场：依通路分类

  • 介绍
  • 非零售
  • 零售

第十二章药品製造市场：依治疗领域

  • 介绍
  • 过敏
  • 心血管疾病
  • 皮肤科
  • 糖尿病
  • 胃肠病学
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 眼科
  • 疼痛管理
  • 心理保健
  • 肺
  • 肾臟疾病
  • 呼吸系统疾病

第十三章美洲药品製造市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太药品製造市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲的药品製造市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 印度製药业提案投资1500亿卢比
    • Glenmark Pharma 在印度推出特力利汀 +Dapagliflozin+Metformin的 FDC 三重疗法，用于治疗第 2 型糖尿病
    • Novo 和 Torrent 扩大合作伙伴关係的可能性
    • 美国FDA核准百时美施贵宝的 Reblozyl (luspatercept-aamt) 作为第一线治疗可能需要输血的低危险骨髓发育不良症候群(MDS) 成人贫血患者
    • 芬兰製造厂将扩建 5,000 万欧元
    • Aenova 与 Galvita 结成策略联盟
    • 诺和诺德投资 21 亿欧元扩建 Hillerod製造地
    • 礼来公司 (Eli Lilly) 在印第安纳州的製造业支出计画中增加了 16 亿美元
    • FDA核准Pluvict 在美国诺华米尔本工厂商业化生产
    • 武田投资 1000 亿日圆在日本新血浆分馏产品生产设施
    • 辉瑞收购 Abzena 的生技药品生产设施

公司名单

  • AstraZeneca PLC
  • Lupin Limited
  • Piramal Pharma Limited
  • Asymchem, Inc.
  • Recipharm AB
  • Biocon Limited
  • AbbVie Inc.
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Merck KGaA
  • Amgen Inc.
  • Advent Pharma Ltd.
  • Johnson & Johnson Services, Inc.
  • Azurity Pharmaceuticals, Inc.
  • Famar Group
  • Zeon Lifesciences Ltd.
  • Actiza Pharmaceutical Pvt. Ltd.
  • Cipla Limited
  • Aenova Group GmbH
  • Boehringer Ingelheim International GmbH
  • Moderna, Inc.
  • Thermo Fisher Scientific Inc.
  • Sun Pharmaceutical Industries Ltd.
  • BioNTech SE
  • Lonza Group AG
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Emcure Pharmaceuticals Limited
  • Veranova, LP
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Novo Nordisk A/S
  • Glenmark Pharmaceuticals Ltd.
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • McKesson Corporation
Product Code: MRR-22146147675F

The Pharmaceutical Manufacturing Market was valued at USD 620.68 billion in 2023, expected to reach USD 672.44 billion in 2024, and is projected to grow at a CAGR of 8.66%, to USD 1,110.17 billion by 2030.

The pharmaceutical manufacturing sector encompasses the production, development, and commercialization of drugs and medical therapies, with a focus on quality, efficiency, and safety in the production of medicinal products. The necessity of this sector is underpinned by the growing global health demands, increasing prevalence of chronic diseases, and the continuous need for innovative therapeutics. Its applications span across the production of APIs (Active Pharmaceutical Ingredients), formulation of finished dosage forms, and advancements in biotechnology. The end-use scope includes hospitals, clinics, research institutes, and retail pharmacies. Key growth factors influencing this market include technological advancements such as automation and AI integration, growing R&D investments, and supportive government policies. Additionally, the rising trend towards personalized medicine and biologics offers significant growth opportunities. Companies can capitalize on these trends by investing in biotech R&D, enhancing their production capabilities, and adopting sustainable practices to reduce environmental impact.

KEY MARKET STATISTICS
Base Year [2023] USD 620.68 billion
Estimated Year [2024] USD 672.44 billion
Forecast Year [2030] USD 1,110.17 billion
CAGR (%) 8.66%

However, the market faces several limitations and challenges, such as stringent regulatory requirements, high costs of drug development, and the complexities involved in biotechnology integration. The global pandemic has also highlighted vulnerabilities in supply chains, reinforcing the need for more resilient systems. Market players are encouraged to explore areas of innovation like digital health tools, advanced drug delivery systems, and the use of big data analytics for optimizing manufacturing processes. Additionally, developing countries present opportunities for market expansion due to increasing healthcare expenditure. The market is highly competitive, with continuous pressure to innovate, demanding agile strategies to maintain market share. Companies should focus on collaborative partnerships, open innovation, and strategic acquisitions to drive growth and overcome existing barriers. Overall, the pharmaceutical manufacturing market is characterized by its dynamic nature, driven by both scientific innovation and regulatory landscapes, thus requiring stakeholders to maintain a proactive and strategic approach to navigate and thrive in this challenging environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Manufacturing Market

The Pharmaceutical Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in global demand for vaccines and drugs
    • Growing pharmaceutical R&D spending
    • Growth in geriatric population and incidence rate of chronic disorders
  • Market Restraints
    • High costs and complexities associated with the pharma production
  • Market Opportunities
    • Rise in the investment and funding programs in the pharmaceutical manufacturing sector
    • Emergence of novel pharmaceutical manufacturing technologies
  • Market Challenges
    • Stringent government regulations for pharmaceutical companies

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Manufacturing Market

A detailed market share analysis in the Pharmaceutical Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Lupin Limited, Piramal Pharma Limited, Asymchem, Inc., Recipharm AB, Biocon Limited, AbbVie Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Pfizer, Inc., Merck KGaA, Amgen Inc., Advent Pharma Ltd., Johnson & Johnson Services, Inc., Azurity Pharmaceuticals, Inc., Famar Group, Zeon Lifesciences Ltd., Actiza Pharmaceutical Pvt. Ltd., Cipla Limited, Aenova Group GmbH, Boehringer Ingelheim International GmbH, Moderna, Inc., Thermo Fisher Scientific Inc., Sun Pharmaceutical Industries Ltd., BioNTech SE, Lonza Group AG, Novartis AG, F. Hoffmann-La Roche Ltd., Emcure Pharmaceuticals Limited, Veranova, L.P., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Sanofi S.A., Novo Nordisk A/S, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, GlaxoSmithKline PLC, and McKesson Corporation.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Formulation, market is studied across Capsules, Injectable, Powders, Sprays, Suspensions, and Tablets.
  • Based on Drug Development Type, market is studied across In-House and Outsource.
  • Based on Route of Administration, market is studied across Inhalations, Oral, Parenteral, and Topical.
  • Based on Drugs, market is studied across Over-the-Counter (OTC) Medicines and Prescription Medicines.
  • Based on Age Group, market is studied across Adults, Children & Adolescents, and Geriatric.
  • Based on Distribution Channel, market is studied across Non-Retail and Retail.
  • Based on Therapy Area, market is studied across Allergy, Cardiovascular Diseases, Dermatology, Diabetes, Gastroenterology, Infectious Disease, Neurology, Oncology, Ophthalmology, Pain Management, Psychiatry, Pulmonary, Renal Disease, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in global demand for vaccines and drugs
      • 5.1.1.2. Growing pharmaceutical R&D spending
      • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complexities associated with the pharma production
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
      • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for pharmaceutical companies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
    • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
    • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
    • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
    • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
    • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
    • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injectable
  • 6.4. Powders
  • 6.5. Sprays
  • 6.6. Suspensions
  • 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

  • 7.1. Introduction
  • 7.2. In-House
  • 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Oral
  • 8.4. Parenteral
  • 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

  • 9.1. Introduction
  • 9.2. Over-the-Counter (OTC) Medicines
  • 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Children & Adolescents
  • 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Non-Retail
  • 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

  • 12.1. Introduction
  • 12.2. Allergy
  • 12.3. Cardiovascular Diseases
  • 12.4. Dermatology
  • 12.5. Diabetes
  • 12.6. Gastroenterology
  • 12.7. Infectious Disease
  • 12.8. Neurology
  • 12.9. Oncology
  • 12.10. Ophthalmology
  • 12.11. Pain Management
  • 12.12. Psychiatry
  • 12.13. Pulmonary
  • 12.14. Renal Disease
  • 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
    • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
    • 16.3.3. Novo, Torrent may Widen Tie-Up
    • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
    • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
    • 16.3.6. Aenova and Galvita Enter Strategic Partnership
    • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
    • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
    • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
    • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Lupin Limited
  • 3. Piramal Pharma Limited
  • 4. Asymchem, Inc.
  • 5. Recipharm AB
  • 6. Biocon Limited
  • 7. AbbVie Inc.
  • 8. Bayer AG
  • 9. Takeda Pharmaceutical Company Limited
  • 10. Eli Lilly and Company
  • 11. Pfizer, Inc.
  • 12. Merck KGaA
  • 13. Amgen Inc.
  • 14. Advent Pharma Ltd.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Azurity Pharmaceuticals, Inc.
  • 17. Famar Group
  • 18. Zeon Lifesciences Ltd.
  • 19. Actiza Pharmaceutical Pvt. Ltd.
  • 20. Cipla Limited
  • 21. Aenova Group GmbH
  • 22. Boehringer Ingelheim International GmbH
  • 23. Moderna, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Sun Pharmaceutical Industries Ltd.
  • 26. BioNTech SE
  • 27. Lonza Group AG
  • 28. Novartis AG
  • 29. F. Hoffmann-La Roche Ltd.
  • 30. Emcure Pharmaceuticals Limited
  • 31. Veranova, L.P.
  • 32. Bristol-Myers Squibb Company
  • 33. Gilead Sciences, Inc.
  • 34. Sanofi S.A.
  • 35. Novo Nordisk A/S
  • 36. Glenmark Pharmaceuticals Ltd.
  • 37. Abbott Laboratories
  • 38. GlaxoSmithKline PLC
  • 39. McKesson Corporation

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 266. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 280. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 286. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 300. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 308. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND PHARMACEU